|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2007-10-1
|
|
pubmed:abstractText |
Human epidermal growth factor receptor 2 (HER-2) expression is associated with increased risk of high-grade disease, nodal metastasis, and absence of estrogen receptors (ERs) in early breast cancer. We tested interactions between ER and HER-2 to determine if they may modulate breast cancer nodal metastasis and proliferation.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:A'HernRogerR,
pubmed-author:Barrett-LeePeterP,
pubmed-author:BartlettJohn M SJM,
pubmed-author:BlissJudith MJM,
pubmed-author:CameronDavid ADA,
pubmed-author:DowsettMitchM,
pubmed-author:EllisIan OIO,
pubmed-author:EllisPaulP,
pubmed-author:HallEmmaE,
pubmed-author:JohnsonLindsayL,
pubmed-author:JohnstonStephenS,
pubmed-author:MallonElizabeth AEA,
pubmed-author:PeckittClareC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4423-30
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17906205-Adult,
pubmed-meshheading:17906205-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17906205-Breast Neoplasms,
pubmed-meshheading:17906205-Female,
pubmed-meshheading:17906205-Humans,
pubmed-meshheading:17906205-Logistic Models,
pubmed-meshheading:17906205-Lymphatic Metastasis,
pubmed-meshheading:17906205-Middle Aged,
pubmed-meshheading:17906205-Multivariate Analysis,
pubmed-meshheading:17906205-Receptor, erbB-2,
pubmed-meshheading:17906205-Receptors, Estrogen,
pubmed-meshheading:17906205-Receptors, Progesterone,
pubmed-meshheading:17906205-Sensitivity and Specificity
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
|
|
pubmed:affiliation |
Endocrine Cancer Research Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom. John.Bartlett@ed.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
